Evidence map›Paper›PMID 36972285›Full record

Trial reportPLoS neglected tropical diseases2023

Randomized trial evaluating an mHealth intervention for the early community-based detection and follow-up of cutaneous leishmaniasis in rural Colombia.

Mabel Castillo, Neal Alexander, Luisa Rubiano, Carlos Rojas, Andrés Navarro, Domiciano Rincon, Leonardo Vargas Bernal, Yenifer Orobio Lerma, Nancy Gore Saravia, Eliah Aronoff-Spencer

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Mabel CastilloCentro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM, Cali, Colombia.
Neal AlexanderCentro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM, Cali, Colombia.ORCID 0000-0002-6707-7876
Luisa RubianoCentro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM, Cali, Colombia.
Carlos RojasFacultad Nacional de Salud Pública, Universidad de Antioquia, Medellín, Colombia.
Andrés NavarroGrupo i2t, Universidad Icesi, Cali, Colombia.
Domiciano RinconGrupo i2t, Universidad Icesi, Cali, Colombia.
Leonardo Vargas BernalGrupo i2t, Universidad Icesi, Cali, Colombia.
Yenifer Orobio LermaCentro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM, Cali, Colombia.
Nancy Gore SaraviaCentro Internacional de Entrenamiento e Investigaciones Médicas, CIDEIM, Cali, Colombia.ORCID 0000-0002-2440-9658
Eliah Aronoff-SpencerUniversity of California, San Diego, California, United States of America.ORCID 0000-0002-6279-5027
Centro Internacional de Entrenamiento e Investigaciones Medicas · COIcesi University · COUniversidad de Antioquia · COUniversity of California San Diego · US

Funding

Vector/Host-Parasite Interface of Leishmaniasis in ColombiaD43TW006589 · FIC · YALE UNIVERSITY · PI GORE SARAVIA, NANCY, TSCHUDI, CHRISTIAN · 2003 to 2024
$4.3M
The Innate Immune Response As A Therapeutic Target For Cutaneous LeishmaniasisU19AI129910 · NIAID · CENTRO INTERNACIONAL (CIDEIM) · PI GORE SARAVIA, NANCY · 2017 to 2021
$2.8M
Applying innovative mobile health technologies to improve diagnosis, treatment and follow-up of patients with leishmaniasis in rural ColombiaR21TW009907 · FIC · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ARONOFF-SPENCER, ELIAH S, GORE SARAVIA, NANCY · 2016 to 2017
$336k
FIC NIH HHS D43 TW006589FIC NIH HHS R21 TW009907NIAID NIH HHS U19 AI129910
6 · The paper itself

Abstract

backgroundIn Latin America, cutaneous leishmaniasis primarily affects dispersed rural communities, that have limited access to the public health system and medical attention. Mobile health (mHealth) strategies have shown potential to improve clinical management and epidemiological surveillance of neglected tropical diseases, particularly those of the skin.

methodsThe Guaral +ST app for Android was designed to monitor cutaneous leishmaniasis treatment and assess therapeutic response. We carried out a randomized trial in the coastal municipality of Tumaco in southwestern Colombia, with parallel arms comparing a) follow-up aided by the app to b) standard institution-based follow-up. Treatment was prescribed according to national guidelines. Follow-up of therapeutic response was scheduled at the end of treatment and at 7, 13 and 26 weeks after the start of treatment. The primary endpoint was the proportion of participants who were monitored at or around week 26, allowing outcome and effectiveness of treatment to be determined.

resultsFollow-up of treatment and outcome assessment was achieved in significantly more patients in the intervention arm than the controls, Of the 75 participants in the two randomized arms, 74 had information on whether or not treatment was followed and outcome determined at or around week 26. Among these, 26/49 (53.1%) were evaluated in the intervention arm, and none (0/25, 0%) in the control arm (difference = 53.1%, 95% confidence interval 39.1-67.0%, p<0.001). Of the 26 participants evaluated at or around week 26 in the intervention arm, 22 (84.6%) had cured. There were no serious adverse events, nor events of severe intensity among patients monitored by CHW using the app.

conclusionThis study provides proof of concept for mHealth to monitor treatment of CL in remote and complex settings, deliver improved care and to provide information to the health system on the effectiveness of treatment as it is delivered to affected populations. CLINICAL

trial registrationISRCTN54865992.

Indexed as

Leishmaniasis, CutaneousTelemedicineColombiaFollow-Up StudiesHumansRural Population

Identifiers

PMID36972285
PMCPMC10079216
OpenAlexW4360995784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.